The Technical Analyst
Tekla Healthcare [HQH]
Exchange: NYSE Sector: Financial Services Industry: Asset Management
Tekla Healthcare Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.06% $16.85
America/New_York / 8 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 814.72 mill |
| EPS: | 1.090 |
| P/E: | 15.46 |
| Earnings Date: | N/A |
| SharesOutstanding: | 48.35 mill |
| Avg Daily Volume: | 0.156 mill |
| RATING 2024-05-08 |
|---|
| C- |
| Strong Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | |||||
| Gr.Profit | n/a | |||||
| Ebit | n/a | |||||
| Asset | n/a | n/a | n/a | |||
| Debt | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 1.56x |
| Company: PE 15.46 | sector: PE 9.91 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.77x |
| Company: PE 15.46 | industry: PE 20.04 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0000 (-100.00%) $-16.85 |
| Date: 2024-05-08 |
| Expected Trading Range (DAY) |
|---|
|
$ 16.63 - 17.07 ( +/- 1.29%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-09 | Goetz Kathleen | Buy | 525 | Common Stock |
| 2024-03-13 | Tse Loretta | Buy | 0 | |
| 2023-12-21 | Goodson Alan R | Buy | 170 | Common stock |
| 2024-01-02 | Reit Todd | Buy | 1 000 | Common Stock |
| 2023-12-28 | Maher Bill | Buy | 1 000 | Common Stock |
| INSIDER POWER |
|---|
| 100.00 |
| Last 54 transactions |
| Buy: 113 661 | Sell: 47 330 |
Forecast:
16:00 - $16.85
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $16.85
Forecast 2: 16:00 - $16.85
Forecast 3: 16:00 - $16.85
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $16.85 (0.06% ) |
| Volume | 0.184 mill |
| Avg. Vol. | 0.156 mill |
| % of Avg. Vol | 117.72 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For HQH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
HQH
Tekla Healthcare Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical devices, and pharmaceuticals industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as current or anticipated market position for services or products, experienced business management, recognized technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index, the S&P 500 Index, and the S&P 1500 Healthcare Index. It was previously known as H&Q Healthcare Investors. Tekla Healthcare Investors was formed on October 31, 1986 and is domiciled in the United States.
Latest Press Releases
2024-03-21 07:59:00 - Press Release
Abrdn Healthcare Investors (hqh), Abrdn Life Sciences Investors (hql), Abrdn healthcare Opportunities Fund (thq), And Abrdn World Healthcare Fund (thw) Announce Investment Team Update
Philadelphia, pa / accesswire / march 21, 2024 / abrdn healthcare investors (nyse:hqh), abrdn life sciences investors (nyse:hql), abrdn healthcare opportunities fund (nyse:thq), and abrdn world healthcare fund (nyse:thw) (collectively, the "funds") each, a closed-end management investment company, announced today the appointment of dr. jason akus as co-lead portfolio manager to the funds alongside dr. daniel omstead. dr. akus has served on the investment team with dr. omstead for over 20 years.
2024-01-10 16:17:00 - Press Release
Abrdn U.s. Closed-end Funds Announce Distribution Payment Details
Philadelphia, pa / accesswire / january 10, 2024 / philadelphia, pa / accesswire / january 10, 2024 / the abrdn u.s. closed-end funds (nyse:asgi, ifn, jeq) (nyse american:hqh, hql, iaf, thq, thw), (the "funds" or individually the "fund"), today announced that the funds paid the distributions noted in the table below on january 10, 2024, on a per share basis to all shareholders of record as of december 29, 2023 (ex-dividend date december 28, 2023). these dates apply to the funds listed below with the exception of abrdn healthcare investors (hqh), abrdn life sciences investors (hql), the abrdn australia equity fund, inc. (iaf), the india fund, inc. (ifn) and the abrdn japan equity fund, inc. (jeq) which will pay on january 10, 2024, to all shareholders of record as of november 22, 2023 (ex-dividend date november 21, 2023).
2023-11-09 16:27:00 - Press Release
Abrdn U.s. Closed-end Funds Announce Distribution Payment Details
Philadelphia, pa / accesswire / november 9, 2023 / the following abrdn u.s. closed-end funds announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per share basis on november 30, 2023 to all shareholders of record as of november 22, 2023 (ex-dividend date november 21, 2023). these dates apply to the funds listed below with the exception of abrdn healthcare investors (hqh), abrdn life sciences investors (hql), the abrdn australia equity fund, inc. (iaf), the india fund, inc. (ifn) and the abrdn japan equity fund, inc. (jeq) which will pay on january 10, 2024, to all shareholders of record as of november 22, 2023 (ex-dividend date november 21, 2023).
2023-10-27 17:20:00 - Press Release
Abrdn Announces Its Appointment To Four U.s. Specialist Healthcare Closed-end Funds, New Board Of Trustees To The Funds And Fund Name Changes
Philadelphia, pa / accesswire / october 27, 2023 / effective close of business today, october 27, 2023, abrdn inc. ("abrdn") assumed responsibility for the management of the four (4) former tekla capital management llc closed-end funds totaling $2.8bn in assets under management (aum) as of october 26, 2023. as noted within the funds' proxy statements and in connection with the change in investment adviser, each fund amended its declaration of trust to change its name as detailed in the chart below effective after close of regular business on october 27, 2023.
2023-10-27 16:57:00 - Press Release
Tekla Capital Management Llc Announces Closing Of Transaction With Abrdn
Tekla capital management llc (tekla) announced today that it has completed the sale of its advisory business to abrdn inc. in addition, effective close of regular business, abrdn was approved as manager to four nyse listed healthcare and biotech thematic closed-end funds, totaling $2.8 bn in assets under management (aum) as of october 26, 2023.
Latest News
2024-05-08 07:35:00 - Seeking Alpha
Buy These 2 Picks If Nothing Else In May
April showers are over, it is time to focus on our top picks for May. Enjoy the warmer weather, improve your health, and improve your portfolio's exposure to the healthcare sector. We look at two outstanding funds to unlock regular income from this sector.
2024-03-07 07:35:00 - Seeking Alpha
I Am Loading Up On 2 Bargain Fat Dividends
I can pay my bills in retirement with cash, and I get that cash from picks like these. Your retirement is going to cost you, so have a way to pay for it. Healthcare and Business Development Companies provide strong income to shareholders.
2024-03-03 09:00:00 - Seeking Alpha
HQH: Healthcare Fund With 11% Income And A High Discount
abrdn Healthcare Investors is a healthcare sector-specific closed-end fund that invests in a portfolio of common stocks in the healthcare industry, heavily weighted in biotechnology. The HQH CEF currently provides a very high yield of 11% plus a high discount of -15% to NAV. HQH has a solid long-term record of nearly 37 years, nearly matching the performance of the S&P 500. However, the recent near- and mid-term performance has been lackluster.
2024-03-02 09:00:00 - Seeking Alpha
How To Invest In A SWAN Portfolio: The Near Perfect Portfolio Strategy
The Near Perfect Portfolio Strategy provides SWAN-like attributes and aims to meet income and growth goals while minimizing volatility and drawdowns. The strategy consists of three buckets: Dividend Growth Investing, High Income (CEF investing), and Hedging (Rotational bucket). Backtesting results over 17 years show that the strategy has the potential to outperform the S&P 500, with lower drawdowns and volatility.
2024-02-25 10:30:00 - Seeking Alpha
Yes, You Can Retire On Dividends, 2 Fat Yields Up To 10%
The market's biggest secret is that you don't need to own a market-wide ETF to succeed. You don't need to sell your assets to fund your retirement. Reject that. Your retirement needs income; let the market pay your way.
2024-02-04 07:58:03 - Seeking Alpha
HQH: Disappointing Track Record
The abrdn Healthcare Investors (HQH) fund has a 36-year track record of underperforming peers that does not create confidence for future results. HQH focuses on mid and large-cap biotech and pharmaceutical companies in late-stage clinical trials i.e. FDA approval catalysts. Capital gains distribution requires reinvestment to achieve compounding returns.
2024-01-31 07:35:00 - Seeking Alpha
I Am Bottom Fishing: 2 Great Dividends +9%
The market is not efficient and it is driven by a few select names. I strongly believe that income is the answer to your expenses. True financial freedom is income overwhelming expenses.
2024-01-26 09:00:00 - Seeking Alpha
The 8% Income Portfolio: 2023 Year-End Review
2023 year-end review of our 8% Income Portfolio. This high-income portfolio earned over $29,000 in distributions amounting to over 14% yield-on-cost basis and roughly 8.6% on average portfolio value. We will provide updates on trades during the year, dividends collected, and overall performance. As usual, we will compare the performance with a traditional 60:40 stock/bond portfolio.
2024-01-16 05:02:15 - Seeking Alpha
5 Closed-End Fund Buys In The Month Of December 2023 (Plus 1 Sell)
Equity and fixed-income markets had another strong month in December, driven by continuing retreating risk-free Treasury rates. We even saw an improvement in the breadth of the overall market, with broader participation lifting some of the beaten-down sectors for the year. That said, closed-end fund discounts remain historically wide, and that continues to drive opportunity in the CEF wrapper.
2024-01-05 11:01:47 - Seeking Alpha
Equity CEFs/ETFs: Top Picks For 2024 - Part II
In Part I of my Top Picks For 2024, I explained why we saw such extreme valuation losses in most equity CEFs in 2023 and what that could-mean for 2024. In my opinion, liquidity was the over-riding factor for why so few stocks, think Magnificent 7, received the lion's share of buy-interest while most everything else suffered, including equity CEFs. But just because the Federal Reserve will continue its Quantitative Tapering doesn't mean that other Fed programs won't increase liquidity in other places.